T. Rowe Price Associates, Inc. 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | T. Rowe Price Associates, Inc. | 2,176,700 3.800% | -2,206,181 (-50.34%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | T. Rowe Price Associates, Inc. | 4,382,881 9.600% | 4,382,881 (New Position) | Filing |